Drug Profile


Alternative Names: (S)-tofisopam; S-tofisopam; Levtofisopam

Latest Information Update: 01 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Pharmos Corporation; Vela Pharmaceuticals
  • Class Antigouts; Anxiolytics; Benzodiazepines; Small molecules; Uricosurics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gout
  • Discontinued CNS disorders; Vasomotor symptoms

Most Recent Events

  • 12 Nov 2012 Efficacy and adverse events data from a phase II trial in Gout presented at the 76th American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2012)
  • 17 May 2012 Final efficacy data from a Phase-II trial in Gout released by Pharmos Corporation
  • 17 May 2012 Pharmos Corporation completes a phase-II trial in Gout in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top